Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced\ 1/7/96.\ Origin:\ Appendix\ 5.\ Amended\ 1/7/98,\ 1/9/99,\ 1/7/2000,\ 30/9/2001,\ 11/3/2002,\ 1/1/2003.$

Pha	rmaxis Ltd	
ABN	ſ	
75	082 811 630	
We	(the entity) give ASX the following i	information.
	rt 1 - All issues must complete the relevant sections (attach so	heets if there is not enough space).
1	⁺ Class of ⁺ securities issued or to be issued	Fully paid ordinary shares
2	Number of *securities issued or to	140,000
2	be issued (if known) or maximum number which may be issued	140,000
	•	
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the	Issue of fully paid ordinary shares upon exercise of options granted under the Pharmaxis Ltd Employee Option Plan.

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes	
5	Issue price or consideration	140,000 shares (PXSAQ	2): \$0.3760
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of options undo Employee Option Plan	er Pharmaxis Ltd
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	17 November 2010	
8	Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)	Number 225,997,684	⁺ Class Fully paid ordinary shares

Appendix 3B Page 2 1/1/2003

⁺ See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class
3,740,000	Options expiring on
	various dates with an
	exercise price of
	\$0.3125 (ASX Code
	PXSAO)
250,000	Options expiring 30
	November 2013 with
	an exercise price of
	\$0.376 (ASX Code
	PXSAQ)
15,000	Options expiring 3
	June 2014 with an
	exercise price of
	\$0.426 (ASX Code
	PXSAU)
225,000	Options expiring 1
	February 2015 with an
	exercise price of
	\$0.8340 (ASX Code
200.000	PXSAY)
290,000	Options expiring 11
	May 2015 with an
	exercise price of
	\$1.147 (ASX Code
700,000	PXSAW)
700,000	Options expiring 4 August 2015 with an
	exercise price of \$1.79
	(ASX Code PXSAZ)
30,000	Options expiring 17
30,000	October 2015 with an
	exercise price of
	\$2.772 (ASX Code
	PXSAA)
	/

⁺ See chapter 19 for defined terms.

35,000	Options expiring 12
	February 2016 with an
	exercise price of
	\$2.194 (ASX Code
	PXSAB)
87,500	Options expiring 31
	May 2016 with an
	exercise price of
	\$2.034 (ASX Code
	PXSAC)
784,750	Options expiring 14
,	August 2016 with an
	exercise price of
	\$1.917 (ASX Code
	PXSAD)
25,000	Options expiring 19
23,000	September 2016 with
	an exercise price of
	\$1.8918 (ASX Code
22.500	PXSAE)
32,500	Options expiring 13
	December 2016 with
	an exercise price of
	\$3.0710 (ASX Code
	PXSAF)
142,500	Options expiring 17
	June 2017 with an
	exercise price of
	\$3.3155 (ASX Code
	PXSAH)
1,464,500	Options expiring 9
	August 2017 with an
	exercise price of
	\$3.3890 (ASX Code
	PXSAL)
150,000	Options expiring 9
	August 2017 with an
	exercise price of
	\$3.3890 (ASX Code
	PXSAI)
200,000	Options expiring 14
	November 2016 with
	an exercise price of
	\$3.2258 (ASX Code
	PXSAK)
	LVOHV)

Appendix 3B Page 4 1/1/2003

⁺ See chapter 19 for defined terms.

Number	+Class
498,750	Options expiring 5
150,750	November 2017 with
	an exercise price of
	\$4.2900 (ASX Code
	PXSAT)
2,000	Options expiring 13
,	December 2017 with
	an exercise price of
	\$4.1373 (ASX Code
	PXSAJ)
11,000	Options expiring 7
,	February 2018 with an
	exercise price of
	\$3.2666 (ASX Code
	PXSAN)
14,000	Options expiring 10
	April 2018 with an
	exercise price of
	\$2.1135 (ASX Code
	PXSAP)
53,500	Options expiring 22
	June 2018 with an
	exercise price of
	\$1.5990 (ASX Code
	PXSAR)
1,216,250	Options expiring 11
	August 2018 with an
	exercise price of
	\$1.8170 (ASX Code
200.000	PXSAS)
200,000	Options expiring 22
	June 2018 with an
	exercise price of
	\$1.5990 (ASX Code
200,000	PXSAV)
200,000	Options expiring 11
	August 2018 with an
	exercise price of \$1.8170 (ASX Code
	PXSAX)
107,500	Options expiring 22
107,500	October 2018 with an
	exercise price of
	\$1.6060 (ASX Code
	,
	PXSAAA)

⁺ See chapter 19 for defined terms.

Number	+Class
35,000	Options expiring 10
	December 2018 with
	an exercise price of
	\$1.1607 (ASX Code
	PXSAAB)
276,000	Options expiring 4
	February 2019 with an
	exercise price of
	\$1.3380 (ASX Code
	PXSAAC)
3,750	Options expiring 22
	April 2019 with an
	exercise price of
	\$1.9574 (ASX Code
	PXSAAD)
1,721,000	Options expiring 22
	June 2019 with an
	exercise price of
	\$2.5498 (ASX Code
	PXSAAE)
525,000	Options expiring 6
	September 2020 with
	a zero exercise price
	(ASX Code PXSAAF)
9,600	Options expiring 23
	September 2020 with
	a zero exercise price
	(ASX Code
	PXSAAG)
n/a	
11/ a	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	

Appendix 3B Page 6 1/1/2003

⁺ See chapter 19 for defined terms.

15	⁺ Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has *security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations
20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders
25	If the issue is contingent on +security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do +security holders sell their entitlements in full through a broker?
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?
32	How do *security holders dispose of their entitlements (except by sale through a broker)?
33	⁺ Despatch date
	3 - Quotation of securities d only complete this section if you are applying for quotation of securities
34	Type of securities (tick one)
(a)	Securities described in Part 1
(b)	All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entit	ies that have ticked box 34(a)
Additi	onal securities forming a new class of securities
Tick to docume	indicate you are providing the information or nts
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders

Appendix 3B Page 8 1/1/2003

⁺ See chapter 19 for defined terms.

36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional +securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b) 38 Number of securities for which +quotation is sought 39 Class of +securities for which quotation is sought 40 Do the *securities rank equally in all respects from the date of allotment with an existing +class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) Number +Class 42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)

Appendix 3B Page 10 1/1/2003

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: ... 16 November 2010 (Company secretary)

Print name:David McGarvey.....

== == == ==

⁺ See chapter 19 for defined terms.